A statistical methodology for drug-drug interaction surveillance.
Interaction between drug substances may yield excessive risk of adverse drug reactions (ADRs) when two drugs are taken in combination. Collections of individual case safety reports (ICSRs) related to suspected ADR incidents in clinical practice have proven to be very useful in post-marketing surveillance for pairwise drug--ADR associations, but have yet to reach their full potential for drug-drug interaction surveillance. In this paper, we implement and evaluate a shrinkage observed-to-expected ratio for exploratory analysis of suspected drug-drug interaction in ICSR data, based on comparison with an additive risk model. We argue that the limited success of previously proposed methods for drug-drug interaction detection based on ICSR data may be due to an underlying assumption that the absence of interaction is equivalent to having multiplicative risk factors. We provide empirical examples of established drug-drug interaction highlighted with our proposed approach that go undetected with logistic regression. A database wide screen for suspected drug-drug interaction in the entire WHO database is carried out to demonstrate the feasibility of the proposed approach. As always in the analysis of ICSRs, the clinical validity of hypotheses raised with the proposed method must be further reviewed and evaluated by subject matter experts.
Norén
G Niklas
GN
WHO Collaborating Centre for International Drug Monitoring in Uppsala, Uppsala, Sweden. niklas.noren@who-umc.org
Sundberg
Rolf
R
Bate
Andrew
A
Edwards
I Ralph
IR
D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D017964:Itraconazole / Q000009:adverse effects; D007654:Ketoconazole / Q000009:adverse effects; D015233:Models, Statistical; D011358:Product Surveillance, Postmarketing; D016593:Terfenadine / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003276:Contraceptives, Oral; D004232:Diuretics; D017964:Itraconazole; D016593:Terfenadine; D007654:Ketoconazole